• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Zepp Health Corporation Reports First Quarter 2024 Unaudited Financial Results

    5/20/24 5:00:00 PM ET
    $ZEPP
    Computer Manufacturing
    Technology
    Get the next $ZEPP alert in real time by email

    MILPITAS, Calif., May 20, 2024 /PRNewswire/ -- Zepp Health Corporation ("Zepp" or the "Company") (NYSE:ZEPP) today reported revenues of US$39.8 million; a basic and diluted net loss per share of US$0.06; and a basic and diluted net loss per ADS of US$0.23 for the first quarter ended March 31, 2024; adjusted basic and diluted net loss per share of US$0.05; and adjusted basic and diluted net loss per ADS of US$0.19. Each ADS represents four Class A ordinary shares.

    Mr. Wang 'Wayne' Huang, Chairman and CEO of Zepp, commented, "In the first quarter of 2024, our revenue came broadly in line with our guidance. Our gross margin performance reached a record high, and our self-branded product sales contributed over 85% of total revenues. Notably, the MAU of our Zepp application has exceeded 10 million, marking an early success of our transformation journey." 

    Wayne continued: "On the products front, we offer a diverse range of series tailored to various market needs. Each series is strategically positioned with a thorough understanding of its competitors and targeted price ranges. We are delighted to observe that our Balance and Active product line has gained more popularity among consumers and KOLs due to the attractive designs and innovative functionalities such as cutting-edge AI functions, a wide range of health services and a diverse selection of watch faces and app ecosystems. This has enabled us to position this product line to a more premium market than before and generate better gross margins. In May, we unveiled the new Amazfit Bip 5 Unity. Through the stainless-steel appearance and bigger screen, we have brought many user-favorite software functions from our mid-to-high-end product lines to Unity, and brought richer apps and watch faces through Zepp OS 3.0 to unity, strengthening our sub-$100 market competitiveness and further expand our market share in emerging markets. We also launched a new product line in May, Helio Ring, which allows users who prefer not to wear watches while sleeping to obtain 24-hour comprehensive health data monitoring. This enhances recovery for athletes and provides readiness analysis for general users, ensuring a holistic user experience with both smartwatches and smart rings. We are the first smartwatch brand to offer such a solution, placing us ahead of our competitors. Our software, especially the proprietary operating system, Zepp OS, has been upgraded to version 3.5, integrating the large-model-based Zepp Flow AI system. This brings large model AI interaction and messaging capabilities to our entire product line. The rapid application and innovation of large model AI technology provides our smartwatch products with opportunities to surpass competitors, showcasing our company's execution and creativity capabilities. Simultaneously, we've strategically invested in our marketing initiatives, prioritizing digital campaigns and outdoor advertising in influential global hubs. This includes prominent placements like the Madrid airport advertising campaign and sponsorship of events such as the recent Rotterdam Marathon. We will launch more advertisements in major global markets to amplify our market presence in coming quarters and collaborate with major global channels like Decathlon, bringing our innovative full-range products to users during this summer sports craze to increase our sales for the second half of the year. With exciting new product launches on the horizon, and supported by our globalized research and management team, our confidence in our roadmap and future opportunities has never been stronger. We are confident that our strategic investments in expanding our brand, enhancing our retail presence, and diversifying our product line will drive growth and contribute to our long-term success."

    Mr. Leon Deng, Zepp's Chief Financial Officer, added, "The first quarter is traditionally a slower season of us, with a significant decline of Xiaomi products sales plus a more subdued new product launch window of our self-branded products, leading to a revenue decline of this quarter compared with last year. However, we continue to achieve a historically high gross margin of 37%, a testament to the superior performance of our self-branded products and a well-calibrated product mix that included a higher proportion of new offerings and reduced clearances. This accomplishment distinctly embodies our strategic intent to prioritize profitability over scale. We judiciously maintained our GAAP and adjusted operational expenses at or below US$30 and US$28 million per quarter, consistent with since the second quarter of last year and in line with our financial forecasts. Our commitment to stringent discretionary spending controls remains unwavering. We persistently pursued a cost-conscious approach while continuing to invest strategically in R&D and marketing initiatives to uphold our competitive edge."

    Leon continued, "We have also maintained vigilant oversight of our working capital throughout the first quarter. Despite a P&L loss, we successfully sustained a positive operating cash flow for the seventh consecutive quarter. In the first quarter of 2023, we initiated a retirement of portions of our short and long-term debt portfolio. Since the first quarter of 2023, we have successfully retired US$46.7 million of debt. As our operating cash flow continues to strengthen, we intend to do more in the coming quarters. With a robust cash reserve of US$132.3 million, we are exceptionally well-positioned to seize strategic investment opportunities and capitalize on potential market expansions. As we progress through 2024, our dedication to operational excellence and strategic foresight remains steadfast. We are resolute in our commitment to enhancing the engagement and satisfaction of our users through continuous innovation in product features and applications. In the interim, we'll persist in our share repurchase program, a tangible demonstration of management's unwavering confidence in the company's trajectory." 

    First Quarter of 2024 Financial Summary













    For the Three Months Ended

    Number in millions, except for percentages and

    per- share/ADS amounts



     Mar. 31, 2024

    Mar. 31, 2023[1]

    Revenue RMB



    287.2

    645.2

    Revenue US$



    39.8

    93.9

    Gross margin

    36.8 %

    15.9 %

    Net loss RMB



    (105.8)

    (136.9)

    Net loss US$



    (14.6)

    (19.9)

    Adjusted EBIT RMB[4]



    (86.4)

    (128.5)

    Adjusted EBIT US$



    (12.0)

    (18.7)

    Net loss attributable to Zepp Health Corporation

    RMB



    (105.5)

    (136.7)

    Adjusted net loss attributable to Zepp Health

    Corporation RMB[2]



    (89.7)

    (112.7)

    Net loss attributable to Zepp Health Corporation

    US$



    (14.6)

    (19.9)

    Adjusted net loss attributable to Zepp Health

    Corporation US$



    (12.4)

    (16.4)

    Basic/diluted net loss per share RMB



    (0.41)

    (0.56)

    Basic/diluted net loss per ADS US$

    (0.23)

    (0.32)

    Adjusted basic/diluted net loss per share RMB[3]



    (0.35)

    (0.46)

    Adjusted basic/diluted net loss per ADS US$

    (0.19)

    (0.27)

    Units shipped in millions

    1.2

    3.5











    [1] The US$ numbers in 2023 are referenced with the prior 6-K disclosures, where translations from RMB to US$ are made at a rate

    of RMB6.8676 to US$1.00, the effective noon buying rate on March 31, 2023 as set forth in the H.10 statistical release of the

    Federal Reserve Board.

    [2] Adjusted net income/(loss) attributable to Zepp Health Corporation is a non-GAAP measure, which excludes share-based

    compensation expenses. The tax effect from the adjustment of the Share-based compensation expenses is nil. See "Reconciliation

    of GAAP and Non-GAAP Results" at the end of this press release.

    [3] Adjusted diluted net income/(loss) is the abbreviation of adjusted net income/(loss) attributable to Zepp Health Corporation,

    which is a non-GAAP measure and excludes share-based compensation expenses attributable to Zepp Health Corporation, and is

    used as the numerator in computation of adjusted basic and diluted net loss per ADS attributable to Zepp Health Corporation. 

    [4] Adjusted EBIT is a non-GAAP financial measure, which is defined as net loss, excluding (i) share-based compensation

    expenses, (ii) income tax (benefit)/ expense, (iii) interest income, (iv) interest expense.



    First Quarter 2024 Financial Results

    Revenues

    Revenues for the first quarter of 2024 reached US$39.8 million, a decrease by 55.5% from the first quarter of 2023. The decrease was primarily due to the decrease in the sales of Xiaomi wearable products, as well as the decrease in sales of our self-branded products as we did not launch any new self-branded products in the first quarter of 2024.

    Total units shipped in the first quarter of 2024 decreased by 65.7% year-over-year to 1.2 million, compared with 3.5 million in the first quarter of 2023.

    Gross Margin

    Gross margin in the first quarter of 2024 was 36.8%, compared to 15.9% in the same period of 2023. We reached another record-high quarterly gross margin since the third quarter of 2023, supported by the strong performance of our self-branded products and a more favourable product mix, with a higher proportion of new products and a reduction in clearance sales, which typically have lower margins.

    Research and Development Expenses

    Research and development expenses in the first quarter of 2024 were US$13.3 million, a decrease by 18.4% year-over-year. This accounted for 33.5% of revenues, compared to 18.3% for the same period in 2023. The decrease was as a result of our refined research and development approaches, as we consistently evaluated resource efficiency to ensure maximum return on investment and productivity. We are committed to investing in new technologies, including AI, to maintain our competitive edge against our peers.

    Selling and Marketing Expenses

    Selling and marketing expenses in the first quarter of 2024 were US$10.7 million, a decrease by 10.1% year-over-year. This accounted for 26.9% of revenues, compared to 13.3% for the same period in 2023.

    The decrease was primarily as a result of our consistent push on retail profitability and channel mix improvement, which included meticulous refinement of our retail channels and strategic staffing arrangements across sales regions. Simultaneously, we've strategically invested in our marketing initiatives, prioritizing digital campaigns and outdoor advertising in influential global hubs. We are committed to investing efficiently in marketing and branding to ensure our sustained growth.  

    General and Administrative Expenses

    General and administrative expenses were US$6.4 million in the first quarter of 2024, a decrease by 7.9% year-over-year. This accounted for 16.0% of revenues, compared with 7.7% in the same period in 2023. The decrease in absolute value was largely attributable to our personnel optimization initiative and strict administrative expense control.

    Operating Expenses

    Total operating expenses for the first quarter of 2024 were US$30.4 million, a decrease by 13.5% year-over-year. Adjusted operating expenses, which exclude share-based compensation, were US$28.2 million. In the first quarter of 2024, we incurred one-off expenses of approximately US$0.5 million. We will maintain our cost-conscious approach in the upcoming quarters. We expect our operating expenses to either remain at current levels or decrease further. Concurrently, we remain committed to investing in R&D and marketing activities to ensure our long-term competitiveness.

    Operating Income/(Loss)

    Operating loss for the first quarter of 2024 was US$15.8 million, a decrease by 24.6% year-over-year. The reduced loss was largely due to the improved gross margin of our self-branded products and reduced operating expenses.

    Net Income/(Loss)

    Net loss attributable to Zepp Health Corporation for the first quarter of 2024 was US$14.6 million, a decrease by 22.8% year-over-year. The adjusted net loss attributable to Zepp Health Corporation, which excludes share-based compensation expenses attributable to Zepp Health Corporation, was US$12.4 million, a decrease by 20.4% year-over-year. 

    Liquidity and Capital Resources

    As of March 31, 2024, the Company had cash and cash equivalents and restricted cash of US$132.3 million, We have generated positive cash flow from our operating activities for the seventh consecutive quarter. We also successfully reduced our total debt, including short-term and long-term bank borrowing balance, by US$0.7 million in the first quarter. We anticipate further reductions in our debt level in the upcoming quarters.

    The Company continued to manage its working capital and inventory efficiently and recorded inventory levels of US$72.8 million as of March 31, 2024.This reached the lowest level since June 30, 2019, marking a decrease by 12.8% and 34.3% compared with December 31, 2023 and March 31, 2023, respectively. We will continue to manage working capital tightly.

    Share Repurchase Program Update

    The Company announced in its third quarter 2021 earnings release that the board had authorized a share repurchase program of up to US$20 million through November 2022. On November 21, 2022, the board authorized a 12-month extension of the Company's share repurchase program. On November 20, 2023, the board further authorized the Company to extend its share repurchase program for another 12 months. Pursuant to the extended share repurchase program, the Company may repurchase its shares in the form of American depositary shares and/or ordinary shares through November 2024 with an aggregate value equal to the remaining balance under the share repurchase program. As of March 31, 2024, the Company had used US$13.4 million to repurchase 5,497,137 ADSs. The Company expects to fund the repurchases under the extended share repurchase program out of its existing cash balance.

    Outlook

    For the second quarter of 2024, the Company's management currently expects net revenues to be between US$40 million and US$55 million, out of which more than 90% are expected to be generated from self-branded products. The new product Amazfit Helio Ring has just been launched, and its contribution to revenues is uncertain.

    This outlook is based on current market conditions and reflects the Company's current and preliminary estimates of market, operating conditions and customer demand, which are all subject to change.

    Conference Call

    The Company's management team will hold a conference call at 7:00 p.m. Eastern Time on Monday, May 20, 2024 (7:00 a.m. Beijing Time on May 21, 2024) to discuss financial results and answer questions from investors and analysts. Listeners may access the call by dialing:

    US (Toll Free):

    +1-888-346-8982

    International:

    +1-412-902-4272

    Mainland China (Toll Free):

    400-120-1203

    Hong Kong (Toll Free):

    800-905-945

    Hong Kong:

    +852-3018-4992

    Participants should dial in at least 10 minutes before the scheduled start time and ask to be connected to the call for "Zepp Health Corporation".

    Additionally, a live and archived webcast of the conference call will be available at http://ir.zepp.com.

    A telephone replay will be available one hour after the call until May 27, 2024 by dialing:

    US Toll Free:

    +1-877-344-7529

    International:

    +1-412-317-0088

    Replay Passcode:

    9164265

    About Zepp Health Corporation

    Zepp Health Corporation (NYSE:ZEPP) is a global smart wearable and health technology leader, empowering users to live their healthiest lives by optimizing their health, fitness, and wellness journeys through its leading consumer brands, Amazfit, Zepp Clarity and Zepp Aura. Powered by its proprietary Zepp Digital Management Platform, which includes the Zepp OS, AI chips, biometric sensors and data algorithms, Zepp delivers cloud-based 24/7 actionable insights and guidance to help users attain their wellness goals. To date, Zepp has shipped over 200 million units, and its products are available in more than 90 countries and regions. Founded in 2013 as Huami Corp., the Company changed its name to Zepp Health Corporation in February 2021 to emphasize its health focus with a name that resonates across languages and cultures globally. Zepp has team members and offices across globe, especially in Europe and USA regions.

    Use of Non-GAAP Measures

    We use adjusted net income/(loss), a non-GAAP financial measure, in evaluating our operating results and for financial and operational decision-making purposes. Adjusted operating expenses represent operating expenses excluding share-based compensation expenses. Adjusted operating income/(loss) represents operating income/(loss) excluding share-based compensation expenses. Adjusted EBIT represents net income/(loss) excluding share-based compensation expenses, income tax (benefit)/expense, interest income and interest expense. Adjusted net income/(loss) represents net income/(loss) excluding share-based compensation expenses, and such adjustment has no impact on income tax. Adjusted net income/(loss) attributable to Zepp Health Corporation is a non-GAAP measure, which excludes share-based compensation expenses attributable to Zepp Health Corporation, and is used as the numerator in computation of adjusted net income/(loss) per share and per ADS attributable to Zepp Health Corporation.

    We believe that adjusted net income/(loss), adjusted EBIT and adjusted net income/(loss) attributable to Zepp Health Corporation help identify underlying trends in our business that could otherwise be distorted by the effect of certain expenses that we include in net income/(loss) and net income/(loss) attributable to Zepp Health Corporation. We believe that adjusted net income/(loss), adjusted EBIT and adjusted net income/(loss) attributable to Zepp Health Corporation provides useful information about our operating results, enhances the overall understanding of our past performance and future prospects and allows for greater visibility with respect to key metrics used by our management in its financial and operational decision-making.

    Adjusted net income/(loss), adjusted EBIT and adjusted net income/(loss) attributable to Zepp Health Corporation, should not be considered in isolation or construed as an alternative to net income/(loss), basic and diluted net income/(loss) per share and per ADS attributable to Zepp Health Corporation or any other measure of performance or as an indicator of our operating performance. Investors are encouraged to review the historical non-GAAP financial measures to the most directly comparable GAAP measures. Adjusted net income/(loss), adjusted EBIT and adjusted net income/(loss) attributable to ordinary shareholders, presented here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to our data. We encourage investors and others to review our financial information in its entirety and not rely on a single financial measure.

    Exchange Rate

    The Company's business is primarily conducted in China. This announcement contains currency conversions of RMB amounts into US$ solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to US$ are made at a rate of RMB7.2203 to US$1.00, the effective noon buying rate on March 29, 2024 as set forth in the H.10 statistical release of the Federal Reserve Board. No representation is made that the RMB amounts could have been, or could be, converted, realized or settled into US$ at that rate on March 29, 2024, or at any other rate.

    Safe Harbor Statement

    This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the cooperation with Xiaomi, the recognition of the Company's self-branded products; the Company's growth strategies; trends and competition in global wearable technology market; changes in the Company's revenues and certain cost or expense accounting policies; governmental policies relating to the Company's industry and general economic conditions in China and the global. Further information regarding these and other risks is included in the Company's filings with the United States Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

    For investor and media inquiries, please contact:

    In China:

    Zepp Health Corporation

    Grace Yujia Zhang

    Email: [email protected] 

    Piacente Financial Communications

    Tel: +86-10-6508-0677

    Email: [email protected]

     

     

    Zepp Health Corporation

    UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

    (Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")

    except for number of shares and per share data, or otherwise noted)







    As of December 31,



    As of March 31,





    2023



    2024





    RMB



    RMB



    US$















    Assets













    Current assets:













    Cash and cash equivalents



    949,036



    895,823



    124,070

    Restricted cash



    48,282



    59,265



    8,208

    Accounts receivable, net



    431,159



    300,813



    41,662

    Amounts due from related parties



    61,098



    23,841



    3,302

    Inventories, net



    602,688



    525,785



    72,820

    Short-term investments



    36,586



    43,169



    5,979

    Prepaid expenses and other current assets



    119,931



    132,620



    18,369

    Total current assets



    2,248,780



    1,981,316



    274,410















    Property, plant and equipment, net



    63,397



    61,981



    8,584

    Intangible asset, net



    70,061



    66,440



    9,202

    Goodwill



    68,023



    69,177



    9,581

    Long-term investments



    1,693,611



    1,686,434



    233,568

    Deferred tax assets



    230,041



    229,464



    31,780

    Amount due from related parties, non-current



    20,954



    23,564



    3,264

    Other non-current assets



    68,852



    59,629



    8,259

    Operating lease right-of-use assets



    48,412



    34,292



    4,749

    Total assets



    4,512,131



    4,212,297



    583,397

     

     

    Zepp Health Corporation

    UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - CONTINUED

    (Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")

    except for number of shares and per share data, or otherwise noted)







    As of December 31, 



    As of March 31,





    2023



    2024





    RMB



    RMB



    US$















    Liabilities













    Current liabilities:













    Accounts payable



    264,726



    152,587



    21,133

    Advance from customers



    1,653



    1,661



    230

    Amount due to related parties



    24,671



    13,797



    1,911

    Accrued expenses and other current liabilities



    315,592



    271,200



    37,561

    Income tax payables



    7,003



    7,337



    1,016

    Notes payable



    475,629



    434,099



    60,122

    Short-term bank borrowings



    12,000



    275,000



    38,087

    Total current liabilities



    1,101,274



    1,155,681



    160,060

    Deferred tax liabilities



    29,601



    29,448



    4,079

    Long-term borrowings



    852,133



    583,820



    80,858

    Other non-current liabilities



    1,916



    1,916



    265

    Non-current operating lease liabilities



    22,697



    21,513



    2,980

    Total liabilities



    2,007,621



    1,792,378



    248,242

     

     

    Zepp Health Corporation

    UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - CONTINUED

    (Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")

    except for number of shares and per share data, or otherwise noted)







    As of December 31,



    As of March 31,





    2023



    2024





    RMB



    RMB



    US$















    Equity













    Ordinary shares



    164



    164



    23

    Additional paid-in capital



    1,750,580



    1,766,355



    244,637

    Treasury stock



    (85,217)



    (89,338)



    (12,373)

    Accumulated retained earnings



    730,731



    625,207



    86,590

    Accumulated other comprehensive income



    96,318



    105,828



    14,657

    Total Zepp Health Corporation shareholders' equity



    2,492,576



    2,408,216



    333,534

    Noncontrolling interest



    11,934



    11,703



    1,621

    Total equity



    2,504,510



    2,419,919



    335,155

    Total liabilities and equity



    4,512,131



    4,212,297



    583,397

     

     

    Zepp Health Corporation

    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")

    except for number of shares and per share data, or otherwise noted)







    For the Three Months Ended March 31,





    2023



    2024





    RMB



    RMB



    US$















    Revenues



    645,183



    287,231



    39,781

    Cost of revenues



    (542,338)



    (181,557)



    (25,145)

    Gross profit



    102,845



    105,674



    14,636

    Operating expenses:

     













    Selling and marketing



    (85,978)



    (77,313)



    (10,708)

    General and administrative



    (49,901)



    (45,961)



    (6,366)

    Research and development



    (117,874)



    (96,136)



    (13,315)

    Total operating expenses



    (253,753)



    (219,410)



    (30,389)

    Operating loss



    (150,908)



    (113,736)



    (15,753)

     

    Other income and expenses:













    Interest income



    4,133



    7,277



    1,008

    Interest expense



    (13,318)



    (10,371)



    (1,436)

    Other (expense)/income, net



    (1,985)



    489



    68

    Gain from fair value change of long-term investments



    3,127



    15,118



    2,094

    Investment income



    234



    -



    -

    Loss before income tax and loss from equity method investments



    (158,717)



    (101,223)



    (14,019)

    Income tax benefits/(expenses)



    24,734



    (514)



    (71)

    Loss before income from equity method investments



    (133,983)



    (101,737)



    (14,090)

    Net loss from equity method investments



    (2,931)



    (4,018)



    (556)

    Net loss



    (136,914)



    (105,755)



    (14,646)

    Less: Net loss attributable to noncontrolling interest



    (194)



    (231)



    (32)

    Net loss attributable to Zepp Health Corporation



    (136,720)



    (105,524)



    (14,614)

    Net loss per share attributable to Zepp Health Corporation













    Basic loss per ordinary share



    (0.56)



    (0.41)



    (0.06)

    Diluted loss per ordinary share



    (0.56)



    (0.41)



    (0.06)















    Net loss per ADS (4 ordinary shares equal to 1 ADS)













    ADS – basic



    (2.23)



    (1.63)



    (0.23)

    ADS – diluted



    (2.23)



    (1.63)



    (0.23)















    Weighted average number of shares used in computing net loss per

    share

    Ordinary share – basic                                                                                             



     

     

    245,133,616



    259,525,679



    259,525,679

    Ordinary share – diluted



    245,133,616



    259,525,679



    259,525,679

     

     

    Zepp Health Corporation

    Reconciliation of GAAP and Non-GAAP Results

    (Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")

    except for number of shares and per share data, or otherwise noted)







    For the Three Months Ended March 31,





    2023



    2024





    RMB



    RMB



    US$















    Total operating expenses



    (253,753)



    (219,410)



    (30,389)

    Share-based compensation expenses[2]



    23,992



    15,775



    2,186

    Total adjusted operating expenses



    (229,761)



    (203,635)



    (28,203)















    Operating loss



    (150,908)



    (113,736)



    (15,753)

    Share-based compensation expenses



    23,992



    15,775



    2,186

    Adjusted operating loss



    (126,916)



    (97,961)



    (13,567)















    Net loss



    (136,914)



    (105,755)



    (14,646)

    Share-based compensation expenses



    23,992



    15,775



    2,186

    Income tax (benefits)/expenses



    (24,734)



    514



    71

    Interest income



    (4,133)



    (7,277)



    (1,008)

    Interest expense



    13,318



    10,371



    1,436

    Adjusted EBIT



    (128,471)



    (86,372)



    (11,961)















    Net loss attributable to Zepp Health Corporation



    (136,720)



    (105,524)



    (14,614)

    Share-based compensation expenses



    23,992



    15,775



    2,186

    Adjusted net loss attributable to Zepp Health

    Corporation[2]



    (112,728)



    (89,749)



    (12,428)



    Adjusted net loss per share attributable to

    Zepp Health Corporation













    Adjusted basic loss per ordinary share



    (0.46)



    (0.35)



    (0.05)

    Adjusted diluted loss per ordinary share



    (0.46)



    (0.35)



    (0.05)















    Adjusted net loss per ADS (4 ordinary shares equal to 1

    ADS)













    ADS – basic



    (1.84)



    (1.38)



    (0.19)

    ADS – diluted



    (1.84)



    (1.38)



    (0.19)















    Weighted average number of shares used in computing

    adjusted net loss per share













    Ordinary share – basic



    245,133,616



    259,525,679



    259,525,679

    Ordinary share – diluted



    245,133,616



    259,525,679



    259,525,679















    Share-based compensation expenses included

    are follows:













    Selling and marketing



    1,155



    1,694



    235

    General and administrative



    10,783



    7,427



    1,029

    Research and development



    12,054



    6,654



    922

    Total



    23,992



    15,775



    2,186

     

     

    Cision View original content:https://www.prnewswire.com/news-releases/zepp-health-corporation-reports-first-quarter-2024-unaudited-financial-results-302150195.html

    SOURCE Zepp Health Corp.

    Get the next $ZEPP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZEPP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ZEPP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zepp Health Corporation Reports First Quarter 2025 Unaudited Financial Results

      MILPITAS, Calif., May 19, 2025 /PRNewswire/ -- Zepp Health Corporation ("Zepp" or the "Company") (NYSE:ZEPP) today announced its unaudited financial results for the first quarter of 2025. First Quarter 2025 Financial and Operating Highlights: Revenue reached US$39 million, out of which Amazfit-branded products grew by 10.2% year-over-year.Gross margin was 37.3% compared with 36.8% in the same period of last yearCash balance was 104 million, after repayment of US$11.5 million short-term debt in the first quarter of 2025.The U.S.-China reached deal to temporarily reduce tariffs; the company has proactively established a dual-sourcing supply chain strategy with production bases in both China a

      5/19/25 8:40:00 PM ET
      $ZEPP
      Computer Manufacturing
      Technology
    • Zepp Health Corporation to Report First Quarter 2025 Financial Results on May 19, 2025

      Earnings Call Scheduled for 9:00 p.m. ET on May 19, 2025 MILPITAS, Calif., May 7, 2025 /PRNewswire/ -- Zepp Health Corporation ("Zepp Health" or the "Company") (NYSE:ZEPP), a global leader in smart wearables and health technology, today announced that it will report its first quarter 2025 unaudited financial results after the market close on Monday, May 19, 2025. Management will hold a conference call at 9:00 p.m. Eastern Time on Monday, May 19, 2025. Listeners may access the call by dialing: US (Toll Free): +1-888-346-8982 International: +1-412-902-4272 Mainland China (Toll Free): 400-120-1203 Hong Kong (Toll Free): 800-905-945 Hong Kong: +852-3018-4992 Participants should dial in at leas

      5/7/25 8:00:00 AM ET
      $ZEPP
      Computer Manufacturing
      Technology
    • Zepp Health Corporation Files 2024 Annual Report on Form 20-F

      MILPITAS, Calif., April 25, 2025 /PRNewswire/ -- Zepp Health Corporation ("Zepp Health" or the "Company") (NYSE:ZEPP), a global leader in smart wearables and health technology, today announced that it has filed its annual report on Form 20-F for the full year ended December 31, 2024 with the U.S. Securities and Exchange Commission (the "SEC"). The annual report can be accessed on the Company's investor relations website at http://ir.zepp.com and on the SEC's website at www.sec.gov. The Company will provide hardcopies of the annual report, free of charge, to its shareholders and ADS holders upon request. Requests should be submitted to [email protected]. About Zepp Health Corporation (NYSE:ZEPP) Z

      4/25/25 5:00:00 PM ET
      $ZEPP
      Computer Manufacturing
      Technology

    $ZEPP
    Financials

    Live finance-specific insights

    See more
    • Zepp Health Corporation Reports First Quarter 2025 Unaudited Financial Results

      MILPITAS, Calif., May 19, 2025 /PRNewswire/ -- Zepp Health Corporation ("Zepp" or the "Company") (NYSE:ZEPP) today announced its unaudited financial results for the first quarter of 2025. First Quarter 2025 Financial and Operating Highlights: Revenue reached US$39 million, out of which Amazfit-branded products grew by 10.2% year-over-year.Gross margin was 37.3% compared with 36.8% in the same period of last yearCash balance was 104 million, after repayment of US$11.5 million short-term debt in the first quarter of 2025.The U.S.-China reached deal to temporarily reduce tariffs; the company has proactively established a dual-sourcing supply chain strategy with production bases in both China a

      5/19/25 8:40:00 PM ET
      $ZEPP
      Computer Manufacturing
      Technology
    • Zepp Health Corporation to Report First Quarter 2025 Financial Results on May 19, 2025

      Earnings Call Scheduled for 9:00 p.m. ET on May 19, 2025 MILPITAS, Calif., May 7, 2025 /PRNewswire/ -- Zepp Health Corporation ("Zepp Health" or the "Company") (NYSE:ZEPP), a global leader in smart wearables and health technology, today announced that it will report its first quarter 2025 unaudited financial results after the market close on Monday, May 19, 2025. Management will hold a conference call at 9:00 p.m. Eastern Time on Monday, May 19, 2025. Listeners may access the call by dialing: US (Toll Free): +1-888-346-8982 International: +1-412-902-4272 Mainland China (Toll Free): 400-120-1203 Hong Kong (Toll Free): 800-905-945 Hong Kong: +852-3018-4992 Participants should dial in at leas

      5/7/25 8:00:00 AM ET
      $ZEPP
      Computer Manufacturing
      Technology
    • Zepp Health Corporation Reports Fourth Quarter and Full Year 2024 Unaudited Financial Results

      MILPITAS, Calif., March 26, 2025 /PRNewswire/ -- Zepp Health Corporation ("Zepp" or the "Company") (NYSE:ZEPP) today announced its unaudited financial results for the fourth quarter of 2024. Fourth Quarter 2024 Financial and Operating Highlights: Revenue reached US$59.5 million representing a 40.2% of quarter over quarter increase, out of which our Amazfit-branded products grew by 43.4% quarter-over-quarter.Gross margin was 36.8% compared with 34.7% in the same period last year.Adjusted operating loss[1] was US$7.4 million, which was the lowest level in 2024.Full Year 2024 Financial and Operating Highlights: Gross margin was 38.5% compared with 26.2% in the full year of 2023.Adjusted operat

      3/26/25 5:00:00 PM ET
      $ZEPP
      Computer Manufacturing
      Technology

    $ZEPP
    Leadership Updates

    Live Leadership Updates

    See more

    $ZEPP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Italian Tennis Star Jasmine Paolini Joins Amazfit as Latest Athlete Ambassador

      Paolini to Wear Amazfit Smart Wearables to Enhance Performance and Recovery. Amazfit logo to appear on Paolini's on-court apparel. Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE:ZEPP), today announced the signing of Italian tennis sensation and World No. 4 Jasmine Paolini as its newest global athlete partner. As part of the multi-year agreement and official smart wearable partnership, Paolini will represent Amazfit by wearing the Amazfit logo and smartwatch on court and the brand's fitness wearables, including Helio Ring, to track sleep and athletic recovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/h

      2/18/25 10:00:00 AM ET
      $ZEPP
      Computer Manufacturing
      Technology
    • Five-Time Olympic Medalist Gabby Thomas Joins Amazfit as Athlete Ambassador

      Amazfit becomes Thomas' first Smartwatch Partner Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE:ZEPP), is proud to announce five-time Olympic Medalist and fashion icon, Gabby Thomas, as the latest ambassador to join the brand's growing roster of elite athletes. As part of the four-year partnership, Thomas will wear Amazfit smartwatches both on the track during training and in competition, and off the track to monitor sleep and recovery. Moreover, through the Zepp app-based food log, Gabby will have easy access to nutrition-tracking as well. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213824479

      2/13/25 12:00:00 PM ET
      $ZEPP
      Computer Manufacturing
      Technology
    • Amendment: SEC Form SC 13G/A filed by Zepp Health Corporation

      SC 13G/A - Zepp Health Corp (0001720446) (Subject)

      11/12/24 6:19:43 AM ET
      $ZEPP
      Computer Manufacturing
      Technology
    • Amendment: SEC Form SC 13G/A filed by Zepp Health Corporation

      SC 13G/A - Zepp Health Corp (0001720446) (Subject)

      10/4/24 8:26:45 AM ET
      $ZEPP
      Computer Manufacturing
      Technology
    • Amendment: SEC Form SC 13G/A filed by Zepp Health Corporation

      SC 13G/A - Zepp Health Corp (0001720446) (Subject)

      10/4/24 8:24:55 AM ET
      $ZEPP
      Computer Manufacturing
      Technology

    $ZEPP
    SEC Filings

    See more
    • Amendment: SEC Form 20-F/A filed by Zepp Health Corporation

      20-F/A - Zepp Health Corp (0001720446) (Filer)

      5/21/25 8:07:07 AM ET
      $ZEPP
      Computer Manufacturing
      Technology
    • SEC Form 6-K filed by Zepp Health Corporation

      6-K - Zepp Health Corp (0001720446) (Filer)

      5/20/25 6:05:58 AM ET
      $ZEPP
      Computer Manufacturing
      Technology
    • Amendment: SEC Form SCHEDULE 13G/A filed by Zepp Health Corporation

      SCHEDULE 13G/A - Zepp Health Corp (0001720446) (Subject)

      5/7/25 11:05:28 AM ET
      $ZEPP
      Computer Manufacturing
      Technology